Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.

Chrysochou C, Power A, Shurrab AE, Husain S, Moser S, Lay J, Salama AD, Kalra PA.

Clin J Am Soc Nephrol. 2010 Mar;5(3):484-9. doi: 10.2215/CJN.06580909.

2.

Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience.

Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA.

J Magn Reson Imaging. 2009 Apr;29(4):887-94. doi: 10.1002/jmri.21708. Review.

PMID:
19306428
3.

Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.

Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A.

AJR Am J Roentgenol. 2015 Sep;205(3):469-78. doi: 10.2214/AJR.14.14268.

PMID:
26295633
4.

Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?

Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM, Watnick SG.

Kidney Int. 2009 Mar;75(5):465-74. doi: 10.1038/ki.2008.496. Review.

5.

Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.

Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC.

Radiology. 2009 Dec;253(3):689-96. doi: 10.1148/radiol.2533090649.

PMID:
19789233
6.

Gadolinium-Induced Fibrosis.

Todd DJ, Kay J.

Annu Rev Med. 2016;67:273-91. doi: 10.1146/annurev-med-063014-124936. Review.

PMID:
26768242
7.

Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?

Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL.

Radiology. 2015 Sep;276(3):741-7. doi: 10.1148/radiol.2015142423.

PMID:
25875973
8.

Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.

Meng H, Grosse-Wortmann L.

J Cardiovasc Magn Reson. 2012 Aug 7;14:56. doi: 10.1186/1532-429X-14-56.

9.

Detection of renal dysfunction by point-of-care creatinine testing in patients undergoing peripheral MR angiography.

Kalisz KR, Davarpanah AH, Usman AA, Collins JD, Carroll TJ, Carr JC.

AJR Am J Roentgenol. 2011 Aug;197(2):430-5. doi: 10.2214/AJR.10.5761.

PMID:
21785090
10.

Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.

Alhadad A, Sterner G, Svensson Å, Alhadad H, Leander P.

Scand J Urol Nephrol. 2012 Feb;46(1):48-53. doi: 10.3109/00365599.2011.621142.

PMID:
22008005
11.

Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.

Bryant BJ 2nd, Im K, Broome DR.

Clin Radiol. 2009 Jul;64(7):706-13. doi: 10.1016/j.crad.2009.04.004.

PMID:
19520215
12.

Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media.

Rees O, Agarwal SK.

Clin Radiol. 2010 Aug;65(8):636-41. doi: 10.1016/j.crad.2010.04.012.

PMID:
20599066
13.

The use of gadolinium for arterial interventions.

Sambol EB, Van der Meer JG, Graham A, Goldstein LJ, Karwowski JK, Dayal R, Derubertis B, Kent KC.

Ann Vasc Surg. 2011 Apr;25(3):366-76. doi: 10.1016/j.avsg.2010.09.012.

PMID:
21288688
14.

Nephrogenic systemic fibrosis: risk factors and incidence estimation.

Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A.

Radiology. 2007 Apr;243(1):148-57.

PMID:
17267695
15.

Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.

Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J.

Invest Radiol. 2015 Jun;50(6):416-22. doi: 10.1097/RLI.0000000000000145.

16.

Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.

Elmholdt TR, Pedersen M, Jørgensen B, Søndergaard K, Jensen JD, Ramsing M, Olesen AB.

Br J Dermatol. 2011 Oct;165(4):828-36. doi: 10.1111/j.1365-2133.2011.10465.x.

PMID:
21692765
17.

Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?

Panesar M, Boateng F, Patel SS, Masood SF, Mahajan P, Patel N, Murray B.

Hemodial Int. 2010 Jul;14(3):289-94. doi: 10.1111/j.1542-4758.2010.00456.x.

PMID:
20662951
18.

Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.

Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J.

Radiology. 2009 Oct;253(1):81-9. doi: 10.1148/radiol.2531082160.

PMID:
19709997
19.

Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.

Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J.

J Magn Reson Imaging. 2009 Dec;30(6):1335-40. doi: 10.1002/jmri.21976.

PMID:
19937927
20.

Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.

Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.

Am J Kidney Dis. 2008 Jun;51(6):966-75. doi: 10.1053/j.ajkd.2007.12.036.

PMID:
18501784

Supplemental Content

Support Center